PPT-Advanced Insulin Therapy: Achieving Better PPG Control in T1DM and T2DM

Moderator Stephen Atkin MBBS MD PhD Professor of Medicine Weill Cornell Medicine Qatar Education City Qatar Foundation Doha Qatar Faculty Tim Heise MD Lead Scientist Science and Administration. 6 94 319 539 634 736 264 5038 Agriculture 07 25 62 264 486 661 339 3180 Arabic 183 302 498 648 761 880 120 6010 Art 04 10 104 493 814 956 44 5090 Biology 75 186 417 623 752 862 138 7115 Business Studies 22 80 206 393 551 705 295 5070 Chemistry 93 190 of Type 1 Diabetes. Type 1 Diabetes Mellitus. Characterized by absolute insulin deficiency. Pathophysiology and etiology. Result of pancreatic beta cell destruction. Prone to ketosis. Total deficit of circulating insulin. Guidelines and Awareness Training. Agenda. Purpose. Contamination and Craters. Recommendations. Summary. Supplier Contamination Prevention. Purpose. Contamination continues to be an issue at PPG. Multiple occurrences related to raw materials, containers or transport. September/October 2015. Summary. Text message to 6,000 patients aged over 18. Paper copies also available. 511 responses. Broad age profile. Large majority express satisfaction. Demand for extended working high. Spring 2017. Introduction. 1. Hello to all patients and carers of the Peel Medical Practice! . Here is the latest newsletter from your Patient Participation Group, or PPG as we are usually called. As well as representing you as Practice patients, we are also your voice. So do let us know about . Tidcombe. Key Questions. How do we encourage eligible parents to register their children for free school meals ahead of the January census?. How do we make sure the funding received through the Pupil Premium is identified and planned?. Add on to insulin. EFFICACY AND TOLERABILITY. OF GLP-1 RECEPTOR AGONISTS. AND DPP-4 INHIBITORS AS ADDON THERAPY TO INSULIN . Complementing Insulin Therapy to Achieve Glycemic. Control. Anthony H. Barnett . Disease. . s_khalilzadeh. A Novel. Cardiometabolic Risk Factor for Type 2 Diabetes. NAFLD and T2DM. NAFLD is closely associated with features of the metabolic. syndrome and is regarded as the hepatic manifestation. SGLT Inhibitors. Program Overview. Glycemic Control in T1DM. Risks Associated With T1DM. Limitations of Insulin Therapy for T1DM. Noninsulin Therapy for T1DM: Pramlintide. T2DM Therapies for T1DM: Metformin. Carbohydrate absorption inhibitors α - glucosidose inhibitors Acarbose : Dose Adverse events Relatively complex network controlling PPG: Determinants of PPG PPG Pre-prandial glycaemic level Meal size and meal content rs2476601 A/G - PTPN22, rs20541 A/G – IL13 , rs29941 A/G – KCTD15 in . pathogenesis. . of. . Type 1 Diabetes in . children. .. Artur . Bossowski MD . PhD. Department . of Pediatric Endocrinology, . By . Dr.Tamara. . Kufoof. MBBS, Assistant Professor, . Pediatric Endocrinologist and Diabetologist, The Hashemite University. 2021/2022. Diabetes mellitus (DM) . . a common, chronic, metabolic disease characterized by . Tom Heaps. Consultant Acute Physician. Case 1. 82-year-old Caucasian female with T2DM (>30 years) and HTN. BMI 19. Metformin. 500mg TDS , . Gliclazide. 40mg BD, . Ramipril. 5mg OD. Admitted with 1/52 of increasing drowsiness, confusion and reduced oral intake. David J. Robinson • Michael J. Coons • Jean-François Yale. Valerie H. Taylor • Gail M. MacNeill • Ronald M. Goldenberg. St. Michael’s Hospital, Toronto, Ontario, Canada. 12. th. May 2017.